Moonwalk’s $70 Million Financing Pushes Adipose-Targeted RNAi Toward Human Testing
Moonwalk Biosciences has closed an oversubscribed $70 million Series B to move its adipose-targeted RNA interference platform deeper into the obesity and cardiometabolic arena. The financing arrives with a clear development agenda: advance the lead candidate, MW101, toward first-in-human studies in late 2027, broaden the tissue-targeted siRNA pipeline, and keep building a discovery engine rooted in human genetics, epigenomics, and multi-omics biology.
The company’s thesis is built around a different therapeutic logic than incretin-based obesity care. Rather than suppressing appetite through central signaling, Moonwalk is aiming directly at adipose tissue, where it intends to modulate pathways tied to energy homeostasis, adipogenesis, lipolysis, and thermogenesis. In practical terms, that means the biology is being redirected at the tissue that stores and releases energy, with the goal of improving body composition rather than driving weight loss through reduced intake alone.
Moonwalk says its preclinical work has shown robust reductions in body weight and fat mass while preserving lean muscle mass and without reducing food intake. That combination matters because loss of lean tissue remains a persistent concern in obesity pharmacotherapy, especially when weight reduction is rapid or pronounced. A platform that can lower adiposity while sparing muscle would be attractive in cardiometabolic disease, where sarcopenia, frailty risk, and functional decline can complicate long-term management.
The company also reports translational evidence consistent with healthy adipose remodeling. In non-human primate studies, a single dose produced durable target engagement in adipose tissue, a finding that supports the possibility of quarterly or even twice-yearly dosing. In a chronic condition such as obesity, infrequent administration could improve adherence and reduce the treatment fatigue that often erodes real-world persistence.
Moonwalk’s approach depends on selective delivery, and that is where the scientific and commercial stakes converge. The platform uses adipose-targeting chemistry licensed from Suzhou Siran Biotechnology Co., Ltd., paired with an AI-enabled discovery system that integrates human genetics, epigenomics, and multi-omics to identify targets not easily reached by conventional drug development. By directing siRNA payloads to adipose tissue while minimizing effects elsewhere, the program seeks to unlock biology that has remained inaccessible to broader systemic therapies.
The financing syndicate reflects that ambition. Alpha Wave and YK Bioventures co-led the round, with participation from Eli Lilly and Company, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures, and Future Ventures. Strategic capital from established life sciences backers suggests confidence not only in the platform concept but also in the translational path toward clinical testing.
Moonwalk has also added Dr. Stephen Djedjos as senior vice president, Clinical Development. He brings more than 20 years of clinical and drug development experience, including senior roles at Kailera Therapeutics, Mineralys Therapeutics, Sana Biotechnology, Gilead Sciences, and Amgen, where he contributed to the development and approval of Repatha®. A physician and pediatric endocrinologist by training, he completed fellowship at Johns Hopkins Hospital. In a field where obesity programs increasingly compete on speed, safety, and mechanistic clarity, experienced clinical leadership can shape how aggressively a platform moves from pharmacology into the clinic.
Medically Modern Bets on Workflow Relief in Diabetes Technology Access
Medically Modern’s new endocrinology partnership addresses a very different problem, but one that is just as consequential in daily practice: the administrative friction around continuous glucose monitors, insulin pumps, and related diabetes supplies. The national durable medical equipment supplier has aligned with an independent, multi-location endocrinology practice in Northern Virginia to manage prior authorization, fulfillment, and referral logistics for CGM and pump orders.
For endocrinology teams, the burden is rarely the device itself; it is the chain of paperwork, verification, benefit routing, and resupply coordination that surrounds it. Medically Modern is embedding itself into that chain by giving the practice real-time visibility into each referred patient’s status, from medical necessity documentation and insurance verification through onboarding and first shipment. The company also tracks ongoing resupply orders and the date of each patient’s last visit.
That matters because many payers tie continued CGM coverage to follow-up intervals, often around six months. When a patient approaches that mark without a visit, the workflow is designed to prompt scheduling before resupply is interrupted. In diabetes care, a lapse in device access can quickly translate into poorer glucose data, less actionable feedback, and a harder road back to stable self-management.
The model is built around the operational pain points that endocrinology practices know well: pharmacy versus DME benefit routing, six-month visit requirements, and the need for reliable supply continuity. Medically Modern says it configures its technology to each practice’s workflow rather than forcing the practice into a generic system. Providers retain full discretion over referrals, clinical decisions remain with the treating team, and participation does not affect referral volume.
The partner practice serves more than 10,000 patients with diabetes. Medically Modern says it can extend the same partnership framework to endocrinology and physician practices nationwide, serving Medicare, Medicare Advantage, and nearly all major commercial payers. The business proposition is straightforward: shift administrative work away from clinicians and staff so they can spend more time on titration, education, and complication prevention.
Corey Deutsch, Medically Modern’s founder and CEO, framed the effort around the paperwork burden that surrounds prescriptions for FreeStyle Libre, Dexcom, and insulin pump systems. Josh Hoffman, the company’s lead engineer, described the partnership model as a way to return time to providers while keeping patients on track for coverage-related visits. Behind both comments sits a familiar clinical problem: even the best diabetes technology fails when access is delayed or when the office team becomes the bottleneck.
Medically Modern says it operates under executed business associate agreements with partner practices and maintains compliance policies addressing HIPAA, the federal Anti-Kickback Statute, and the Stark Law. Those guardrails are central in a space where DME distribution, payer documentation, and referral relationships can raise regulatory scrutiny. The practical test will be whether the model reduces delays without adding another layer of coordination for practices already stretched thin.
For endocrinology, the two announcements point in different directions but share the same underlying theme. One company is trying to rewrite obesity pharmacology at the level of adipose tissue. The other is trying to make sure patients with diabetes can actually get the technology their clinicians prescribe. Both are aiming at the same clinical endpoint from opposite sides of the system: better metabolic care that can be delivered reliably, and without unnecessary friction.